Deal Watch: Artios Links Up With Novartis On DNA Damage Response Modifiers
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.
You may also be interested in...
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Multiple non-vaccine options for COVID-19 continue to progress, with promising new clinical results for Sorrento's small molecule drug and a supplementary approval in Japan for Chugai's antibody combo. Meanwhile, China's CRDC has in-licensed technology for Ligand to apply to an oral antiviral it is developing. Meanwhile, SK Biosciences' novel nanoparticle vaccine is positive in early trials.
Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge.